Literature DB >> 6146820

Mass screening for neuroblastoma in infants in Japan. Interim report of a mass screening study group.

T Sawada, M Hirayama, T Nakata, T Takeda, N Takasugi, T Mori, K Maeda, R Koide, Y Hanawa, A Tsunoda.   

Abstract

A mass screening system for the early detection by means of a vanillylmandelic acid test of neuroblastoma in 6-month-old infants in Japan has been developed in eight districts. 16 of the 281 939 infants screened by this test had neuroblastoma, equivalent to a very high incidence of 1 in 17 621. 15 of the 16 children with neuroblastoma are alive; the other child died 1 month after surgery. This mass screening system for neuroblastoma used in infancy can help to improve prognosis in infants with this malignant disorder.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6146820     DOI： 10.1016/s0140-6736(84)90311-8

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


  26 in total

Review 1.  Screening for neuroblastoma.

Authors:  S N Huddart; J R Mann
Journal:  Arch Dis Child       Date:  1991-11       Impact factor: 3.791

2.  Screening for neuroblastoma in the north of England.

Authors:  L Parker; A W Craft; G Dale; S Bell; M Cole; A C McGill; J A Seviour; J Smith
Journal:  BMJ       Date:  1992-11-21

3.  Successful treatment of infants with localized neuroblastoma based on their MYCN status.

Authors:  Tomoko Iehara; Minoru Hamazaki; Tatsuro Tajiri; Yoshifumi Kawano; Michio Kaneko; Hitoshi Ikeda; Hajime Hosoi; Tohru Sugimoto; Tadashi Sawada
Journal:  Int J Clin Oncol       Date:  2012-03-02       Impact factor: 3.402

4.  Neuroblastoma mass screening in infancy in Kyoto, Japan.

Authors:  T Sawada; H Kawakatsu; T Sugimoto; Y Horii; K Kuroda; H Hosoi; T Saida; T Hino; T Michihata
Journal:  Indian J Pediatr       Date:  1987 Nov-Dec       Impact factor: 1.967

5.  VMA mass screening program of neuroblastoma for infants in Nagoya City, Japan.

Authors:  K Kodama; T Nakata; J Ishii; K Mitani; H Tsunooka; A Masaoka; M Aoyama
Journal:  Am J Public Health       Date:  1985-02       Impact factor: 9.308

6.  Fluctuation in the concentrations of vanillylmandelic acid and homovanillic acid in mass screening for neuroblastoma.

Authors:  M Nishi; H Miyake; T Takeda; K Yamashiro; N Takasugi; J Hanai; T Kawai
Journal:  Eur J Pediatr       Date:  1990-09       Impact factor: 3.183

7.  Neuroblastoma detected by mass screening: the Tumor Board's role in its treatment.

Authors:  Tadaharu Okazaki; Sumio Kohno; Jun-ichi Mimaya; Shiro Hasegawa; Naoto Urushihara; Atsushi Yoshida; Shinya Kawano; Junichi Kusafuka; Yasuo Horikoshi; Yoshifumi Takashima; Katsuhiko Aoki; Minoru Hamazaki
Journal:  Pediatr Surg Int       Date:  2003-12-19       Impact factor: 1.827

8.  Lineage analysis of early and advanced tubular adenocarcinomas of the stomach: continuous or discontinuous?

Authors:  Takahisa Nakayama; Zhi-Qiang Ling; Ken-ichi Mukaisho; Takanori Hattori; Hiroyuki Sugihara
Journal:  BMC Cancer       Date:  2010-06-21       Impact factor: 4.430

9.  Dependence receptor UNC5D mediates nerve growth factor depletion-induced neuroblastoma regression.

Authors:  Yuyan Zhu; Yuanyuan Li; Seiki Haraguchi; Meng Yu; Miki Ohira; Toshinori Ozaki; Atsuko Nakagawa; Toshikazu Ushijima; Eriko Isogai; Haruhiko Koseki; Yohko Nakamura; Cuize Kong; Patrick Mehlen; Hirofumi Arakawa; Akira Nakagawara
Journal:  J Clin Invest       Date:  2013-06-17       Impact factor: 14.808

10.  Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas.

Authors:  Frank Westermann; Daniel Muth; Axel Benner; Tobias Bauer; Kai-Oliver Henrich; André Oberthuer; Benedikt Brors; Tim Beissbarth; Jo Vandesompele; Filip Pattyn; Barbara Hero; Rainer König; Matthias Fischer; Manfred Schwab
Journal:  Genome Biol       Date:  2008-10-13       Impact factor: 13.583
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.